Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Orchestra BioMed Holdings (OBIO) Gross Margin (2022 - 2025)

Historic Gross Margin for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to 94.31%.

  • Orchestra BioMed Holdings' Gross Margin rose 12000.0% to 94.31% in Q3 2025 from the same period last year, while for Sep 2025 it was 93.01%, marking a year-over-year increase of 3000.0%. This contributed to the annual value of 92.27% for FY2024, which is 9900.0% down from last year.
  • Per Orchestra BioMed Holdings' latest filing, its Gross Margin stood at 94.31% for Q3 2025, which was up 12000.0% from 94.5% recorded in Q2 2025.
  • In the past 5 years, Orchestra BioMed Holdings' Gross Margin ranged from a high of 96.22% in Q1 2023 and a low of 77.08% during Q4 2024
  • Moreover, its 4-year median value for Gross Margin was 94.34% (2024), whereas its average is 91.73%.
  • Within the past 5 years, the most significant YoY rise in Orchestra BioMed Holdings' Gross Margin was 90600bps (2023), while the steepest drop was -131300bps (2023).
  • Orchestra BioMed Holdings' Gross Margin (Quarter) stood at 95.19% in 2022, then decreased by -14bps to 82.06% in 2023, then dropped by -6bps to 77.08% in 2024, then increased by 22bps to 94.31% in 2025.
  • Its Gross Margin stands at 94.31% for Q3 2025, versus 94.5% for Q2 2025 and 94.93% for Q1 2025.